Early results from trials of ivosidenib (AG-120), a novel inhibitor of mutant IDH1, inIDH1-mutated acute myelogenous leukemia (AML) indicated an overall response rate of 41.6% and a complete remission rate of 21.6%77. The gene discussed is IDH1; the disease is acute myeloid leukemia.